Opening book details…
Can I read PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment on EtoBox?
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment by Robert B. Kargbo is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.
What is PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment about?
The anti-apoptotic BCL-2 protein family members, including BCL-2, BCL-XL, and MCL-1, have been established as promising therapeutic targets for cancer treatment, as evidenced by the FDA approval of venetoclax in 2016. Researchers have redoubled their efforts to design analogs that exhibit enhanced pharmacokinetic and pharmacodynamic characteristics. This Patent Highlight features PROTAC compounds that demonstrate potent and selective BCL-2 degradation, with potential applications in the treatment of cancer, autoimmune disorders, and immune system diseases. Important Compound Classes.
Who reads PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment?
It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.
- Author
- Robert B. Kargbo
- Publisher
- American Chemical Society (ACS)
- Published
- 2023
- Language
- EN
- Field
- Biochemistry, Genetics and Molecular Biology (Life Sciences)